Our Story

In 2002, a successful Proof of Concept trial showing structural and functional regeneration of myocardial tissue as well as reperfusion of an infarct zone after a recent Acute Myocardial Infarct (AMI) was performed and included 7 myocardial infarction patients with a very poor short-term prognosis. Based on the objective of building a robust and automated bioprocessing technology aimed at producing a large amount of purified stem cells, CellProthera has developed a proprietary technology platform made of an automated expansion device (StemXpand®) and its disposable kit (StemPack®). The final cell product ProtheraCytes® is made of CD34+ stem cells which have been confirmed to have potential for regeneration of various damaged tissues. ProtheraCytes® is now registered as an ATMP – Advanced Therapy Medicinal Product – within the classification of Tissue Engineered product by the European Medicines Agency. Our most advanced program is the regeneration of damaged heart tissue after severe AMI to prevent Heart Failure (HF). It is an unmet medical need for a million patients per year only in the US, Europe and Japan.

Science & Technology

Adult stemcells are a natural resource available and capable of long-term self renewal. Our cellular product, ProtheraCytes® based on specific stemcells CD34+ together with our know how and technology is safe and has the power to regenerate multiple tissues.

News, medias & events



(Strasbourg & On line) 07-12-2021

Innovation therapies day

(Besançon, FR) 10-2021

Healthtech Innovation Days 

(Paris, FR) 10-2021

6e Bioproduction Congress

(Lyon, FR) 09-2021


Scientific partners

The Institut de Recherche en Hématologie et Transplantation (IRHT),
a private non-profit medical research centre in Mulhouse that has been pioneering adult stem cells researches for over 20 years. www.irht.fr

CellProthera’s privileged partner, the IRHT Mulhouse is at the origin of most of the achievements and scientific knowledge of CellProthera. Led by Professor Philippe HENON, the IRHT has a large expertise in the field of Blood Stem Cells (HSC), from more than 25 years of work and research.

Industrial partners

Specialized in the development of innovative automated equipment for life sciences including culture reactors microorganisms, CellProthera has partnered with Bertin Technologies from the start of the project in 2009. www.bertin.fr In this regard, the company has designed the prototype of the cell expansion automated for producing and expanding autologous blood stemcells.

A family company which specializes in the design and manufacturing of mechatronic systems. For over 40 years, it operates in the demanding environment of pharmaceutical and medical industries. www.strebweil.com Streb & Weil accompanies CellProthera in its therapeutic industrialization process and gives its expertise for the development of cell expansion automates.

For 30 years, E3 Cortex meets the needs of design and manufacturing of special packaging dedicated to chemistry, pharmacy, biology, robotics, aeronautics, transplantation, etc. www.e3cortex.fr The company is responsible for designing and producing packaging kits developed by CellProthera.

Institutional partners

As a French world-class cluster dedicated to therapeutic innovations, BioValley France is the one-stop contact to optimize any R&D development or business project in Europe, both in drug development and medical technologies. Located in Alsace region, part of the famous French-German-Swiss BioValley and with a unique concentration of international life sciences & healthcare players, BioValley France helps any Life Sciences & Healthcare companies interested in new projects and partnerships in Europe: to search outstanding scientific or industrial partners to develop very innovative R&D projects, to find the best innovative technology, patent or scientific expertise, or to set up and locate in Alsace region. www.biovalley-france.com

Since the 1 January 2013, Bpifrance, the French public investment bank, brings together the financing activities of OSEO (innovation, guarantee, credit) and those of equity investments led by FSI, FSI Régions et CDC Entreprises. Its ambition is to help businesses, ranging from start-ups to medium-sized companies, and occasionally large companies, to innovate, invest, grow and export. Bpifrance, by sharing the risks with its private and public partners, provides a continuum of financing, from short-term credits to equity capital, that meets the needs relating to each stage of businesses life cycle. bpifrance is a support of choice for CellProthera in its development. www.bpifrance.fr

France Biotech is the French association of biotechnology companies and partners. Its mission is to contribute to making the French biotechnology industry a leader in Europe. www.france-biotech.org


The contribution of each employee is essential to the development and success of CellProhtera.